Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Lipitor (atorvastatin by Year
Lipitor (atorvastatin — Upjohn spin-off Nov 2020) [legacy] ($M) ($M)
Pfizer Lipitor (atorvastatin: $1,973M in FY2019, down 4.3% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
1,973
Period ended Dec 31, 2019
Change on a year earlier
-4.3%
2,062 in FY2018
History
3 years
Since FY2017
Sources
1
Form 10-K (filed 2020-02-27)
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-27) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lipitor (atorvastatin — Upjohn spin-off Nov 2020) [legacy] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 1,973 | -4.3% | Form 10-K (filed 2020-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 2,062 | +7.7% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 1,915 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Lipitor (atorvastatin ($M), annual FY2017–FY2019 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lipitor-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.